Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacy of EMDR Versus CBT for Post-Traumatic Stress Disorder in Pakistan

24 septembre 2026 mis à jour par: Dr. Anwar Khan, Khushal Khan Khattak Univeristy, Karak, Pakistan

Efficacy of Eye Movement Desensitization and Reprocessing Versus Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder and Comorbid Disorders in Pakistan: A Full-Fledged Randomized Controlled Trial

This randomized controlled trial compares Eye Movement Desensitization and Reprocessing (EMDR) therapy with Cognitive Behavioral Therapy (CBT) for the treatment of post-traumatic stress disorder (PTSD) in Pakistan. The study examines whether EMDR is at least as effective as CBT in reducing PTSD symptoms over time. It also assesses changes in symptoms of depression and anxiety that commonly occur alongside PTSD. Participants are randomly assigned to receive either EMDR or CBT, and their symptoms are assessed at different stages of treatment and follow-up.

Aperçu de l'étude

Description détaillée

This study is a multi-center, single-blind, two-group randomized controlled trial designed to compare Eye Movement Desensitization and Reprocessing (EMDR) therapy with Cognitive Behavioral Therapy (CBT) for the treatment of post-traumatic stress disorder (PTSD) and associated symptoms of depression and anxiety.

The study is conducted in sequential phases. During the initial phase, the psychometric properties of the assessment measures are examined and treatment fidelity is evaluated to determine whether EMDR and CBT are delivered consistently and in accordance with their respective treatment protocols. The subsequent phase focuses on the comparative clinical effectiveness of EMDR and CBT.

Eligible participants with PTSD are randomly allocated to either the EMDR or CBT treatment condition using a covariate-adaptive stratified randomization procedure with a 1:1 allocation ratio. Treatment is delivered face-to-face by clinical psychologists trained in the respective psychotherapeutic approaches. The number of treatment sessions varies according to participants' clinical needs and symptom severity.

The primary objective is to examine whether EMDR is non-inferior to CBT in reducing PTSD symptoms. Additional objectives are to examine changes in PTSD symptoms over the course of treatment and follow-up, assess changes in associated depressive and anxiety symptoms, and explore the relationship between changes in PTSD symptoms and changes in these comorbid symptoms.

PTSD symptoms are assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Depressive symptoms are assessed using the Hamilton Depression Rating Scale (HDRS), and anxiety symptoms are assessed using the State-Trait Anxiety Inventory (STAI). Assessments are conducted at baseline, during treatment, at the end of treatment, and at follow-up.

Treatment fidelity is also evaluated by assessing therapists' adherence to the EMDR and CBT protocols and their competence in delivering the interventions.

Type d'étude

Interventionnel

Inscription (Réel)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Islamabad, Pakistan, 4400
        • Dr Farzana Bashir Clinic, Gulberg Green Office# G-67, Opal Sqaure, Islamabad (Wellness Clinic )
      • Peshawar, Pakistan, 25000
        • Paraplegic Center Peshawar
      • Peshawar, Pakistan, 25000
        • Psychiatry Unit & Rehabilitation Center, Lady Reading Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

15 ans à 60 ans (Enfant, Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Aged 15 to 60 years.
  • Confirmed diagnosis of post-traumatic stress disorder (PTSD), with PTSD identified as the primary clinical condition.
  • Associated symptoms of depression and anxiety at screening.
  • Able to participate in face-to-face psychotherapy and perform the basic eye and hand movements required for the treatment procedures.
  • Able to provide informed consent and communicate sufficiently to participate meaningfully in assessment and psychotherapy.

Exclusion Criteria:

  • Younger than 15 years or older than 60 years.
  • Significant limitations in eye or hand movement, or inability to perform the basic movements required for participation in the treatment procedures.
  • Prolonged unconsciousness or otherwise unable to maintain sufficient consciousness to participate meaningfully in assessment or psychotherapy.
  • Does not meet the screening criteria for PTSD, or PTSD is not the primary clinical condition.
  • Severe intellectual impairment that substantially limits the ability to understand, communicate, or participate in the assessment and psychotherapy procedures.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Eye Movement Desensitization and Reprocessing (EMDR) Therapy

Participants assigned to this arm received face-to-face Eye Movement Desensitization and Reprocessing (EMDR) therapy delivered by clinical psychologists trained in EMDR. Treatment followed an eight-stage EMDR protocol for PTSD, with culturally adapted procedures used where appropriate. The number of sessions varied according to symptom severity and clinical need, generally ranging from 6 to 14 sessions, typically delivered once per week. PTSD, depressive, and anxiety symptoms were assessed at baseline, during treatment, at the end of treatment, and at follow-up

Eye Movement Desensitization and Reprocessing (EMDR) therapy was delivered face-to-face by clinical psychologists trained and certified in EMDR. Treatment followed an eight-stage EMDR protocol for post-traumatic stress disorder (PTSD), incorporating culturally adapted procedures where appropriate for the Pakistani clinical context. Treatment included history-taking and treatment planning, preparation, assessment, desensitization using bilateral stimulation, installation of adaptive cognitions, body scan, closure, and reevaluation. The number of sessions was determined according to participants' symptom severity and clinical needs and generally ranged from 6 to 14 sessions, typically delivered once per week.

Comparateur actif: Cognitive Behavioral Therapy (CBT)

Participants assigned to this arm received face-to-face Cognitive Behavioral Therapy (CBT) delivered by clinical psychologists trained in CBT. Treatment followed a structured trauma-focused CBT protocol, with culturally adapted procedures used where appropriate. The number of sessions varied according to symptom severity and clinical need, generally ranging from 6 to 14 sessions, typically delivered once per week. PTSD, depressive, and anxiety symptoms were assessed at baseline, during treatment, at the end of treatment, and at follow-up.

Cognitive Behavioral Therapy (CBT) was delivered face-to-face by clinical psychologists trained and certified in CBT. Treatment followed a structured trauma-focused CBT protocol for post-traumatic stress disorder (PTSD), with culturally adapted procedures used where appropriate for the Pakistani clinical context. Treatment included assessment and engagement, psychoeducation, relaxation, affective modulation, cognitive coping and restructuring, trauma narrative work, exposure-based procedures, caregiver involvement where appropriate, and enhancement of safety. The number of sessions was determined according to participants' symptom severity and clinical needs and generally ranged from 6 to 14 sessions, typically delivered once per week.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Post-traumatic stress disorder symptoms
Délai: Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

PTSD symptom severity was assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). CAPS-5 scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in PTSD symptoms over time and to compare the EMDR and CBT treatment groups.

Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Depressive symptoms
Délai: Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HDRS). Scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in depressive symptoms over time in the EMDR and CBT treatment groups.

Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
Anxiety symptoms
Délai: Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Anxiety symptoms were assessed using the State-Trait Anxiety Inventory (STAI). Scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in anxiety symptoms over time in the EMDR and CBT treatment groups.

Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 mai 2022

Achèvement primaire (Réel)

28 février 2024

Achèvement de l'étude (Réel)

1 mars 2024

Dates d'inscription aux études

Première soumission

1 février 2023

Première soumission répondant aux critères de contrôle qualité

23 mai 2024

Première publication (Réel)

30 mai 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data (IPD) will not be shared. The study involves sensitive mental health, trauma-related, and clinical information, and the consent and ethical framework for the study did not provide for public or external sharing of individual-level participant data. Aggregate study findings may be reported in publications and other research outputs.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner